In particular, licensed DCs is expected to upregulate costimulatory molecules, particularly 4-1BB, which in turn may serve as the target for SA-4-1BBL for antigen uptake and cross-presentation for the generation of effective CD8+ T cell responses against tumor, which we have recently reported [26]. Here, CD8A is linked to neoplasm.